Edina Cenko/Redcliffe Cardiology and Erik Stroes/amsterdamumc.nl
Sep 13, 2026, 16:51
Edina Cenko: AZURE-HeFH Highlights the LDL-C Treatment Gap in HeFH
Edina Cenko, Past-Chairperson ESC Working Group on Coronary Pathophysiology and Microcirculation at European Society of Cardiology, shared on LinkedIn:
“Presented by Erik Stroes at ESC Congress 2026, baseline cohort data from the Phase 3 AZURE-HeFH trial evaluating the novel oral PCSK9 inhibitor laroprovstat vs placebo.
Lifelong cumulative exposure makes aggressive LDL-C lowering essential in HeFH—yet less than 25% hit guideline targets on conventional oral LLT.
- N is 472 genetically or clinically confirmed HeFH participants
- Approximately 21% with prior ASCVD
- 94% on statins (more than 80% high-intensity) and 73.1% on ezetimibe
- Mean baseline LDL-C: 2.95 mmol/L despite intensive combination background therapy
These findings underline the profound implementation gap in HeFH.
Looking forward to primary 12-week and 52-week safety or efficacy outcomes.”
Other posts featuring Edina Cenko on Hemostasis Today.
-
Sep 13, 2026, 17:28Jim Hoffman: New Potential Predictive Biomarker for Lupus Nephritis
-
Sep 13, 2026, 17:08W. Alberto Sifuentes Giraldo: Urticarial Vasculitis Clinical Features, Systemic Involvement, and Treatment
-
Sep 13, 2026, 16:58Let’s Debunk Some Myths about Blood in SCD – ASCO
-
Sep 13, 2026, 16:56William Wallace: A Magnesium Ion Decides Whether Your Brain Learns or Not
-
Sep 13, 2026, 16:54Meet NBDF’s 2026 Excellence Fellowship Recipients – National Bleeding Disorders Foundation
-
Sep 13, 2026, 16:52Kaloyan Takov: Native Lp(a) Carries a Distinct Triglyceride Signature Linked to Cardiovascular Disease
-
Sep 13, 2026, 16:51Axay Tomar: How Simulation-Based Education Shapes Safer Transfusion Practices
-
Sep 13, 2026, 16:49William Aird: Why Is LDH Elevated In Splenic Infarction?
-
Sep 13, 2026, 16:48David McIntosh: PPTA Calls for Action on the Global Shortage of Plasma-Derived Medicines